Everest Medicines Sees Differentiated Strategy Leading To Trodelvy Success
China Situation Key
Executive Summary
Focused on the Chinese Market, the Shanghai-based bioventure is pushing ahead with a differentiated clinical development strategy for its top in-licensed asset Trodelvy, as an uphill fight looms over the antibody-drug conjugate therapy outside of China, the company’s president says in an interview.
You may also be interested in...
Gilead Summits Takeback Of Trodelvy Rights In Deal With Everest
Deal Snapshot: Through subsidiary Immunomedics, Gilead will pay $280m up front to gain the remaining global rights to the drug, at a time when Everest’s business model has encountered some difficulties in China.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Explained: How China’s Public Payer Wants To Define Innovative Drugs
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter revealed during a recent industry event. The disclosure has unnerved pharma companies, which have been hit by sharp drug price discounts that were required by the public payer in exchange for reimbursement coverage.